11/4/2013 9:39:09 AM
Addex Therapeutics (SIX: ADXN), a leading
company pioneering allosteric modulation-based drug discovery and development
announced today entering a collaboration with the National Institute on Drug
Abuse (NIDA), a component of the National Institutes of Health (NIH) to evaluate
the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator
(PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and
addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and
ADX88178 in a battery of preclinical models to study their potential as
treatments for nicotine and cocaine addiction.
Help employers find you! Check out all the jobs and post your resume.
comments powered by